Sanofi

Aventis Pharmaceuticals Inc.

Dorothea Kominos

Nicolas Baurin

Han Li

Alla Pritsker

Govindan Subramanian

Matthew Davison

Xin Chen

Jie Zhang

Michael L Edwards

Frank Halley

Andrew David Morley

Herve Bouchard

Dominique Damour

Conception Nemecek

Tahir Nadeem Majid

Francois Clerc

Paul Joseph Cox

Charles J Gardner

Brian L Pedgrift

Timothy A Gillespy

Shelley Amendola

Chantal Carrez

Christopher D Edlin

Justine Yeun Quai Lai

Olivier Houille

Daniel N A Bezard

Stephanie Deprets

Philip Janiak

Magali Mathieu

Alexey Rak

Bruno Poirier

Francis Duffieux

Patrick Grailhe

Christopher Ryan Morgan

Stephanie D Deprets

Cyril Daveu

The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kallidin activity or detect Kallidin or des-Arg10-Kallidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg-Bradykinin and des-Arg-Kallidin-like peptide.

Nucleic acids encoding antibodies to Kallidin and des-Arg-Kallidin and host cells comprising the same

[object Object]

The invention provides antibodies that specifically bind to Plasminogen Activator Inhibitor type-1 (PAI-1), The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-PAI-1 antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies to modulate PAI-1 activity or detect PAI-1, either in vitro or in vivo, are also provided. The disclosure further provides methods of making antibodies that specifically bind to PAI-1 in the active conformational state.

Antibodies to plasminogen activator inhibitor-1 (PAI-1) and uses thereof

The invention is directed to physiologically active compounds of general formula (I):&#x2014; and compositions containing such compounds; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

Azaindoles for inhibiting aurora2 and other kinases

The invention is directed to physiologically active compounds of general formula (I):and compositions containing such compounds; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

Azaindoles

Growing community of inventors

Millington, NJ, United States of America

Dorothea Kominos